Publications des scientifiques de l'IRD

Liégeois Florian, Boyer S., Eymard-Duvernay Sabrina, Carrieri P., Kouanfack C., Domyeum J., Maradan G., Ducos J., Mpoudi-Ngole E., Spire B., Delaporte E., Kuaban C., Vidal Laurent, Laurent Christian, EVOLCAM Study Group. (2020). Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM). BMC Infectious Diseases, 20 (1), [10 p.].

Titre du document
Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM)
Année de publication
2020
Type de document
Article référencé dans le Web of Science WOS:000514588700006
Auteurs
Liégeois Florian, Boyer S., Eymard-Duvernay Sabrina, Carrieri P., Kouanfack C., Domyeum J., Maradan G., Ducos J., Mpoudi-Ngole E., Spire B., Delaporte E., Kuaban C., Vidal Laurent, Laurent Christian, EVOLCAM Study Group
Source
BMC Infectious Diseases, 2020, 20 (1), [10 p.]
BackgroundHepatitis B is a major concern in Africa, especially in HIV-infected patients. Unfortunately, access to hepatitis B virus (HBV) testing and adequate treatment remains a challenge in the continent. We investigated HBV testing, treatment, and virologic suppression in HIV-infected patients followed up as part of Cameroon's national antiretroviral programme.MethodsA cross-sectional survey was performed in adult patients receiving antiretroviral therapy (ART) in 19 hospitals in the Centre and Littoral regions in Cameroon. The proportions of patients tested for hepatitis B surface antigen (HBsAg) prior to the study were compared among all study hospitals using the Chi-square test. The association of individual and hospital-related characteristics with HBV testing and virologic suppression was assessed using multilevel logistic regression models.ResultsOf 1706 patients (women 74%, median age 42years, median time on ART 3.9years), 302 (17.7%) had been tested for HBsAg prior to the study. The proportion of HBV-tested patients ranged from 0.8 to 72.5% according to the individual hospital (p <0.001). HBV testing was lower in women (adjusted odds ratio [aOR] 0.64, 95% confidence interval [CI] 0.46-0.89, p =0.010) and higher in patients who initiated ART in 2010 or later (aOR 1.66, 95% CI 1.23-2.27, p <0.001). Of 159 HBsAg-positive patients at the time of the study (9.3%), only 97 (61.0%) received Tenofovir + Lamivudine (or Emtricitabine). Of 157 coinfected patients, 114 (72.6%) had a HBV viral load <10IU/mL. HBV suppression was higher in patients with a HIV viral load <300 copies/mL (aOR 3.46, 95% CI 1.48-8.09, p= 0.004) and lower in patients with increased ALT level (aOR 0.86 per 10IU/mL increase, 95% CI 0.75-0.97, p =0.019).ConclusionsA substantial proportion of HIV/HBV coinfected patients were at higher risk of liver disease progression. Improving the management of HBV infection in the routine healthcare setting in Africa is urgently required in order to achieve the 2030 elimination targets. Micro-elimination of HBV infection in people living with HIV could be an easier and cost-effective component than more widely scaling up HBV policies.
Plan de classement
Santé : généralités [050] ; Entomologie médicale / Parasitologie / Virologie [052]
Description Géographique
CAMEROUN
Localisation
Fonds IRD [F B010077935]
Identifiant IRD
fdi:010077935
Contact